Myocardial Inflammation at FDG PET/MRI and Clinical Outcomes in Symptomatic and Asymptomatic Participants after COVID-19 Vaccination

ABSTRACT Purpose To evaluate potential cardiac sequelae of COVID-19 vaccination at 2-month follow-up and relate cardiac symptoms to myocardial tissue changes on fluorodeoxyglucose (FDG) PET/MRI, blood biomarkers, health-related quality of life, and adverse outcomes. Materials and Methods In this prospective study (ClinicalTrials.gov: NCT04967807), a convenience sample of individuals aged ≥17 years were enrolled after COVID-19 vaccination and were categorized as symptomatic myocarditis (new cardiac symptoms within 14 days of vaccination and met diagnostic criteria for acute myocarditis), symptomatic no myocarditis (new cardiac symptoms but did not meet criteria for myocarditis), and asymptomatic (no new cardiac symptoms). Standardized evaluation was performed 2 months after vaccination, including cardiac fluorine 18 FDG PET/MRI, blood biomarkers, and health-related quality of life. Statistical analysis included Kruskal-Wallis and Fisher exact tests. Results Fifty-four participants were evaluated a median of 72 days (IQR: 42, 91) after COVID-19 vaccination, 17 symptomatic with myocarditis (36±[SD]15 years, 13 males), 17 symptomatic without myocarditis (42±12 years, 7 males), and 20 asymptomatic (45±14 years, 9 males). No participants in the symptomatic without myocarditis or asymptomatic groups had focal FDG-uptake, myocardial edema or impaired ventricular function. Two participants with symptomatic myocarditis had focal FDG-uptake, and three had high T2 on MRI. Health-related quality of life was lower in the symptomatic myocarditis group than the asymptomatic group. There were no adverse cardiac events beyond myocarditis in any participant. Conclusions At two-month follow-up, FDG PET/MRI showed evidence of myocardial inflammation in 2/17 participants diagnosed with acute myocarditis early after COVID-19 vaccination, but not in symptomatic and asymptomatic participants without acute myocarditis. Keywords: Myocarditis, Vaccination, COVID-19, PET/MRI, Cardiac MRI, FDG-PET

[1]  Xia Li,et al.  Prognosis of Myocarditis Developing After mRNA COVID-19 Vaccination Compared With Viral Myocarditis , 2022, Journal of the American College of Cardiology.

[2]  S. Zimmer,et al.  Cardiac magnetic resonance follow-up of COVID-19 vaccine associated acute myocarditis , 2022, Frontiers in Cardiovascular Medicine.

[3]  P. Thavendiranathan,et al.  Thoracic and Cardiac Imaging / Imagerie cardiaque et imagerie thoracique , 2022 .

[4]  B. Wintersperger,et al.  Clinical Impact of Cardiac MRI T1 and T2 Parametric Mapping in Patients with Suspected Cardiomyopathy. , 2022, Radiology.

[5]  P. Veit-Haibach,et al.  Diagnostic Accuracy of Cardiac MRI versus FDG PET for Cardiac Sarcoidosis: A Systematic Review and Meta-Analysis. , 2022, Radiology.

[6]  R. Wald,et al.  Cardiac MRI and Clinical Follow-up in COVID-19 Vaccine–associated Myocarditis , 2022, Radiology.

[7]  R. Wald,et al.  Myocarditis Following COVID-19 Vaccination , 2022, Cardiology Clinics.

[8]  B. Tai,et al.  Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis , 2022, The Lancet Respiratory Medicine.

[9]  J. Cavalcante,et al.  Cardiac Magnetic Resonance Imaging Midterm Follow Up of COVID-19 Vaccine–Associated Myocarditis , 2022, JACC: Cardiovascular Imaging.

[10]  R. Wald,et al.  Myocardial Injury Pattern at MRI in COVID-19 Vaccine–Associated Myocarditis , 2022, Radiology.

[11]  Michael John Smith,et al.  Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. , 2022, JAMA.

[12]  J. Fish,et al.  Combined Cardiac Fluorodeoxyglucose-Positron Emission Tomography/Magnetic Resonance Imaging Assessment of Myocardial Injury in Patients Who Recently Recovered From COVID-19. , 2022, JAMA cardiology.

[13]  P. Veit-Haibach,et al.  Combined simultaneous FDG-PET/MRI with T1 and T2 mapping as an imaging biomarker for the diagnosis and prognosis of suspected cardiac sarcoidosis , 2021, European Journal of Hybrid Imaging.

[14]  J. Udell,et al.  Cardiac MRI Assessment of Nonischemic Myocardial Inflammation: State of the Art Review and Update on Myocarditis Associated with COVID-19 Vaccination , 2021, Radiology. Cardiothoracic imaging.

[15]  T. Grist,et al.  Myocarditis Associated with mRNA COVID-19 Vaccination , 2021, Radiology.

[16]  P. Hotez,et al.  Myocarditis With COVID-19 mRNA Vaccines , 2021, Circulation.

[17]  J. Gargano,et al.  Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[18]  E. Nagel,et al.  Standardized image interpretation and post-processing in cardiovascular magnetic resonance - 2020 update , 2020, Journal of Cardiovascular Magnetic Resonance.

[19]  B. Wintersperger,et al.  Loss of base-to-apex circumferential strain gradient assessed by cardiovascular magnetic resonance in Fabry disease: relationship to T1 mapping, late gadolinium enhancement and hypertrophy , 2019, Journal of Cardiovascular Magnetic Resonance.

[20]  Matthias Gutberlet,et al.  Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. , 2018, Journal of the American College of Cardiology.

[21]  R. Wald,et al.  Noninvasive hematocrit assessment for cardiovascular magnetic resonance extracellular volume quantification using a point-of-care device and synthetic derivation , 2018, Journal of Cardiovascular Magnetic Resonance.

[22]  R. Blankstein,et al.  Prognostic Value of Cardiac Magnetic Resonance Tissue Characterization in Risk Stratifying Patients With Suspected Myocarditis. , 2017, Journal of the American College of Cardiology.

[23]  R. Herfkens,et al.  Initial Experience With Simultaneous 18F-FDG PET/MRI in the Evaluation of Cardiac Sarcoidosis and Myocarditis , 2017, Clinical nuclear medicine.

[24]  J. Francis.  Vaccine Associated Myocarditis , 2017 .

[25]  P. Heusch,et al.  Feasibility of FDG-PET in myocarditis: Comparison to CMR using integrated PET/MRI , 2018, Journal of Nuclear Cardiology.

[26]  E. Miller,et al.  Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis , 2014, Journal of Nuclear Cardiology.

[27]  N. Funabashi,et al.  Determination of optimum periods between onset of suspected acute myocarditis and ¹⁸F-fluorodeoxyglucose positron emission tomography in the diagnosis of inflammatory left ventricular myocardium. , 2013, International journal of cardiology.

[28]  Tiina Heliö,et al.  Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2013, European heart journal.

[29]  MinJae Lee,et al.  Multiple imputation for left‐censored biomarker data based on Gibbs sampling method , 2012, Statistics in medicine.

[30]  Aki Tsuchiya,et al.  Canadian Valuation of EQ-5D Health States: Preliminary Value Set and Considerations for Future Valuation Studies , 2012, PloS one.

[31]  H. Ohira,et al.  18F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[32]  G. Kolodny,et al.  Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. , 2008, AJR. American journal of roentgenology.

[33]  T. Yokoyama,et al.  Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  M. Cerqueira,et al.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. , 2002, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[35]  M. Cerqueira,et al.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. , 2002, Circulation.